Results 1 to 10 of about 16,893 (133)

Secondary Pulmonary Alveolar Proteinosis Associated With Ruxolitinib After Bone‐Marrow Transplantation: A Case With Transient Improvement Following Drug Discontinuation [PDF]

Respirology Case Reports
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor used to treat steroid‐refractory graft‐versus‐host disease, wherein pulmonary alveolar proteinosis (PAP) is a rare complication.
Taiki Yanagi, Maki Asami‐Noyama, Kaoru Yamamoto, Yoshinobu Hoshii, Yasushi Ichiyama, Masatoshi Okimura, Tetsuya Fujii, Junki Suizu, Misa Harada, Keita Murakawa, Kazuki Hamada, Toshiaki Utsunomiya, Yoriyuki Murata, Keiji Oishi, Nobutaka Edakuni, Tomoyuki Kakugawa, Tsunahiko Hirano, Kazuto Matsunaga   +17 more
doaj   +2 more sources

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

IDCases, 2020
Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the
Kei Kasahara, Naokuni Hishiya, Yuki Suzuki   +2 more
exaly   +3 more sources

Ruxolitinib treatment in patients with polycythemia vera reduces variant allele frequency and improves symptom burden and hematocrit control [PDF]

Therapeutic Advances in Hematology
Background: In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV). Objective: Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.
Claire N. Harrison, Jean-Jacques Kiladjian, J. E. Hamer-Maansson, Ahmad Naim, Francesca Palandri, Francesco Passamonti   +5 more
doaj   +2 more sources

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +1 more source

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2021
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao, Yanmin Zhao, Guifang OuYang, Jimin Shi, Jimin Shi, Yi Luo, Yi Luo, Yamin Tan, Yamin Tan, Jian Yu, Jian Yu, Huarui Fu, Huarui Fu, Xiaoyu Lai, Xiaoyu Lai, Lizhen Liu, Lizhen Liu, He Huang, He Huang   +18 more
doaj   +1 more source

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

Blood Cancer Journal, 2023
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Ambrine Sahal, Estelle Saland, Valérie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Fanny Granat, Laura Poillet, Caroline Marty, Isabelle Plo, Jean-Emmanuel Sarry, Stéphane Manenti, Véronique Mansat-De Mas, Carine Joffre   +18 more
doaj   +1 more source

Exploring redox vulnerabilities in JAK2V617F-positive cellular models

Hematology, Transfusion and Cell Therapy, 2021
Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima, Lucia Rossetti Lopes, João Agostinho Machado-Neto   +2 more
doaj   +1 more source

Enzalutamide and Ruxolitinib [PDF]

Hospital Pharmacy, 2013
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Susan A, Hobson, J Aubrey, Waddell, Dominic A, Solimando   +2 more
openaire   +2 more sources

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Frontiers in Oncology, 2021
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun, Yingxin Sun, Yifeng Cai, Jia Chen, Jia Chen, Jiannong Cen, Jiannong Cen, Mingqing Zhu, Mingqing Zhu, Jinlan Pan, Jinlan Pan, Depei Wu, Depei Wu, Aining Sun, Aining Sun, Suning Chen, Suning Chen   +16 more
doaj   +1 more source

JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Clinical & Translational Immunology, 2023
Objectives Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT).
Yigeng Cao, Jiali Wang, Shan Jiang, Mengnan Lyu, Fei Zhao, Jia Liu, Mingyang Wang, Xiaolei Pei, Weihua Zhai, Xiaoming Feng, Sizhou Feng, Mingzhe Han, Yuanfu Xu, Erlie Jiang   +13 more
doaj   +1 more source